Vebreltinib met amplification data analysis

Vebreltinib is an oral small molecule tyrosine kinase inhibitor, mainly targeting patients with MET gene amplification or exon 14 skipping mutations of non-small cell lung cancer (NSCLC) and other solid tumors. MET amplification is a driver gene abnormality that can activate the HGF/MET signaling pathway and promote tumor cell proliferation, invasion and drug resistance. In patients with non-small cell lung cancer, MET amplification is often associated with treatment resistance, especially in the resistance mechanism that occurs after the use of EGFR inhibitors.

Multiple studies have shown that boricitinib has high clinical activity inMET amplification-positive patient groups. By targeting the ATP binding site of MET, the drug can effectively inhibit the autophosphorylation of MET receptor tyrosine kinase, block abnormal signals in the downstream PI3K/AKT and RAS/ERK pathways, thereby inhibiting tumor growth. Among patients with different degrees of MET amplification, boricitinib showed a stronger inhibitory effect on tumor cells with high levels of amplification, while patients with low levels of amplification also responded to a certain extent, but the efficacy may be relatively limited.

Additionally, the effects of bricitinib have shown potential across tumor types. For example, some patients with MET-amplified glioma and gastric cancer have observed controllable disease stabilization and partial response in clinical trials. There are various detection methods for MET amplification, including fluorescence in situ hybridization (FISH) and gene sequencing (NGS). These detection results can help select patients who may benefit and guide individualized treatment plans.

Overall, the application of boricitinib in MET amplification-related tumors provides a new option for targeted therapy. Its data shows that precise inhibition of driver gene abnormalities can improve the disease control rate of patients to a certain extent and provide hope for drug-resistant patient groups.

Reference materials:https://www.asymbio.com.cn/